Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren(University of Miami Health System), Rochelle E. Curtis(National Institutes of Health), Gèrard Socié(Hôpital Saint-Louis), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lois B. Travis(Indiana University – Purdue University Indianapolis), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter M. Banks(National Cancer Institute), J. Douglas Rizzo, Elaine S. Jaffe(National Cancer Institute), Mary M. Horowitz(Medical College of Wisconsin), Douglas W. Kingma(National Cancer Institute), Ethel S. Gilbert(National Institutes of Health), Kathleen A. Sobocinski(Medical College of Wisconsin), H. Joachim Deeg(Fred Hutch Cancer Center)
Cited by 400
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k